HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) today announced the termination of its Letter of Intent Agreement to purchase Bryomed International, Inc. The Company looks forward to maintaining the relationship between the parties and will continue to pursue a vendor agreement as Bryomed continues the registration process of its products with the FDA. HST will also discontinue its efforts to purchase the worldwide rights for the manufacturing and distribution of Salicinium.
